psalexa
P&S Market Research - A market research firm

Wnt Signaling Pathway Inhibitors Therapeutics Pipeline

Wnt Signaling Pathway Inhibitors Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

Delivery : 1-2 Working Days
Report Code: LS11148
Available Format:

Wnt signalling pathway with improper activation results in development of cancer and insufficient activation of Wnt signalling pathway can result in tissue damage and degeneration. Thus, Wnt signalling pathway has been a very attractive target for the development of anti-cancer therapies and pro-regeneration therapies. Since, activation of Wnt signalling pathway is an efficient therapeutic strategy for tissue damage, but is dangerous for cancer patients. Thus, therapies are required to be developed with extreme care to prevent the risks of cancer complications. This provides opportunities to the companies for the development of specific targeted therapies rather than blocking the Wnt signalling altogether for the treatment of various type of cancers, including colorectal cancer, gastric cancer and pancreatic cancer, with better efficacy and reduced side-effects.

A wide range of diseases such as different types of cancer and degenerative diseases, can be treated by deregulation of components involved in Wnt/β-catenin signalling pathway. The complicated regulation of β-catenin at its various sites provides alternative targets for therapeutic interventions. Also, researches have demonstrated that moderate weakening of Wnt signalling can eliminate its carcinogenic potential.

Samumed, LLC is in the process of developing SM04755 as a small molecule which acts as a Wnt signalling pathway inhibitor for the treatment of plaque psoriasis, tendinitis, colorectal cancer, gastric cancer, liver cancer, pancreatic cancer, and scleroderma. Some of the companies focusing on the pipeline for Wnt signalling pathway inhibitors include Samumed, LLC, BetaCat Pharmaceuticals, Inc., Can-Fite BioPharma Ltd. and others.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licencing, grants, technology and others.

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 3250
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 4000
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 7750

Pre-Purchase Enquiry